San Francisco, United States
Heartflow, founded in 2010, stands at the forefront of AI-driven coronary artery disease management, an essential sector within Biotechnology and Health Care. Their slogan, "Decisive Coronary Care," encapsulates their mission to transform the diagnosis and treatment of CAD, the leading global cause of death.
Headquartered in the United States, with additional offices in key locations like California, Texas, the UK, and Japan, Heartflow leverages advanced technology to create precise, personalized 3D heart models, significantly aiding clinicians in early disease intervention. This global company has treated over 600,000 patients and boasts adoption by more than 1,800 leading institutions, reshaping the standard of coronary care.
Their innovative platform, backed by more than 625 peer-reviewed publications and aligned with ACC/AHA guidelines, positions Heartflow as a leader poised for growth. Their most recent $419.00M Post-Ipo Equity investment, led by Bain Capital Life Sciences, further underscores investor confidence in their growth trajectory.
